Great ariticle, would you like-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

MrDT
2021-06-09

Great ariticle, would you like to share it?

老年癡呆概念股起飛啦！你看好嗎？

今天，美國食品和藥物管理局FDA批准了$百健(BIIB)$ 的阿爾茨海默氏症（老年癡呆症）治療藥物Aduhelm，公司股價盤中一度大漲60%：據阿爾茨海默氏症協會估計，有超過600萬美國人患有此病，因爲無法得到有效的治療，到2050年，這一數字預計將上升到近1300萬。據有關專家分析，我國老年癡呆症患者比美國還要嚴重，數量可能是美國的2倍。得了老年癡呆症的人，會逐漸喪失記憶力，直到喪失動機力、無法自理，最終喪失身體機能，導致死亡。這種破壞記憶的疾病是美國第六大死亡原因，治療選擇非常有限，診斷後的平均餘命僅爲爲三到九年。百健的藥物獲批是革命性的，因爲這是美國批准的第一種減緩老年癡呆症認知能力下降的藥物，也是近20年來第一種治療該疾病的新藥，對於老年癡呆症患者來說就是救命神藥。除了百健外，其他阿爾茨海默病領域的公司也在爭取獲得批准: $Cassava Sciences Inc(SAVA)$ 一度大漲17%；$禮來(LLY)$一度大漲12%。更多相關閱讀請看：老年癡呆症有救了！20年來第一次，FDA批准百健新藥 …… 最後，大家聊一聊：你是否看好老年癡呆概念股？精彩留言用戶可獲得888社區積分噢！

老年癡呆概念股起飛啦！你看好嗎？

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":180948958,"tweetId":"180948958","gmtCreate":1623172620774,"gmtModify":1704197709998,"author":{"id":3583314024186480,"idStr":"3583314024186480","authorId":3583314024186480,"authorIdStr":"3583314024186480","name":"MrDT","avatar":"https://static.tigerbbs.com/526fbb83a2be159f8b7662f14d9b1333","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great ariticle, would you like to share it?</p></body></html>","htmlText":"<html><head></head><body><p>Great ariticle, would you like to share it?</p></body></html>","text":"Great ariticle, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/180948958","repostId":117128195,"repostType":1,"repost":{"magic":2,"id":117128195,"tweetId":"117128195","gmtCreate":1623124022713,"gmtModify":1704196577319,"author":{"id":3502767768442965,"idStr":"3502767768442965","authorId":3502767768442965,"authorIdStr":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","vip":2,"userType":2,"introduction":"Mainstreet_Trades","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":38889,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/a27c61de2bfbc3d5974a2de163edf9ff","width":"840","height":"470"},{"img":"https://static.tigerbbs.com/e4fd1aa1ac3f59d90eeb5c35b5e3a73b","width":"674","height":"459"},{"img":"https://static.tigerbbs.com/5e8de7cc84d3d4b2514a72e4863ebfe7","width":"400","height":"257"}],"coverImages":[{"img":"https://static.tigerbbs.com/a27c61de2bfbc3d5974a2de163edf9ff","width":"840","height":"470"},{"img":"https://static.tigerbbs.com/e4fd1aa1ac3f59d90eeb5c35b5e3a73b","width":"674","height":"459"},{"img":"https://static.tigerbbs.com/5e8de7cc84d3d4b2514a72e4863ebfe7","width":"400","height":"257"}],"title":"老年癡呆概念股起飛啦！你看好嗎？","extraTitle":"","html":"<html><head></head><body><p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/5e8de7cc84d3d4b2514a72e4863ebfe7\" tg-width=\"400\" tg-height=\"257\">今天，美國食品和藥物管理局FDA批准了<a target=\"_blank\" href=\"https://laohu8.com/S/BIIB\">$百健(BIIB)$</a> 的阿爾茨海默氏症（老年癡呆症）治療藥物Aduhelm，公司股價盤中一度大漲60%：<img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/a27c61de2bfbc3d5974a2de163edf9ff\" tg-width=\"840\" tg-height=\"470\">據阿爾茨海默氏症協會估計，有超過600萬美國人患有此病，因爲無法得到有效的治療，到2050年，這一數字預計將上升到近1300萬。據有關專家分析，我國老年癡呆症患者比美國還要嚴重，數量可能是美國的2倍。<img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/e4fd1aa1ac3f59d90eeb5c35b5e3a73b\" tg-width=\"674\" tg-height=\"459\">得了老年癡呆症的人，會逐漸喪失記憶力，直到喪失動機力、無法自理，最終喪失身體機能，導致死亡。這種破壞記憶的疾病是美國第六大死亡原因，治療選擇非常有限，診斷後的平均餘命僅爲爲三到九年。</p> <p>百健的藥物獲批是革命性的，因爲這是美國批准的第一種減緩老年癡呆症認知能力下降的藥物，<b>也是近20年來第一種治療該疾病的新藥，</b>對於老年癡呆症患者來說就是救命神藥。</p> <p>除了百健外，其他阿爾茨海默病領域的公司也在爭取獲得批准:</p> <ul> \n <li><a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> 一度大漲17%；<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$禮來(LLY)$</a>一度大漲12%。</li> \n</ul> <p>更多相關閱讀請看：<a href=\"https://laohu8.com/TW/117902499\" target=\"_blank\">老年癡呆症有救了 ！20年來第一次，FDA批准百健新藥</a></p> <p>……</p> <p>最後，大家聊一聊：</p> <ul> \n <li><span style=\"color:rgba(248,9,9,1);\"><b>你是否看好老年癡呆概念股？</b></span></li> \n</ul> <p>精彩留言用戶可獲得888社區積分噢！</p></body></html>","htmlText":"<html><head></head><body><p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/5e8de7cc84d3d4b2514a72e4863ebfe7\" tg-width=\"400\" tg-height=\"257\">今天，美國食品和藥物管理局FDA批准了<a target=\"_blank\" href=\"https://laohu8.com/S/BIIB\">$百健(BIIB)$</a> 的阿爾茨海默氏症（老年癡呆症）治療藥物Aduhelm，公司股價盤中一度大漲60%：<img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/a27c61de2bfbc3d5974a2de163edf9ff\" tg-width=\"840\" tg-height=\"470\">據阿爾茨海默氏症協會估計，有超過600萬美國人患有此病，因爲無法得到有效的治療，到2050年，這一數字預計將上升到近1300萬。據有關專家分析，我國老年癡呆症患者比美國還要嚴重，數量可能是美國的2倍。<img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/e4fd1aa1ac3f59d90eeb5c35b5e3a73b\" tg-width=\"674\" tg-height=\"459\">得了老年癡呆症的人，會逐漸喪失記憶力，直到喪失動機力、無法自理，最終喪失身體機能，導致死亡。這種破壞記憶的疾病是美國第六大死亡原因，治療選擇非常有限，診斷後的平均餘命僅爲爲三到九年。</p> <p>百健的藥物獲批是革命性的，因爲這是美國批准的第一種減緩老年癡呆症認知能力下降的藥物，<b>也是近20年來第一種治療該疾病的新藥，</b>對於老年癡呆症患者來說就是救命神藥。</p> <p>除了百健外，其他阿爾茨海默病領域的公司也在爭取獲得批准:</p> <ul> \n <li><a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> 一度大漲17%；<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$禮來(LLY)$</a>一度大漲12%。</li> \n</ul> <p>更多相關閱讀請看：<a href=\"https://laohu8.com/TW/117902499\" target=\"_blank\">老年癡呆症有救了 ！20年來第一次，FDA批准百健新藥</a></p> <p>……</p> <p>最後，大家聊一聊：</p> <ul> \n <li><span style=\"color:rgba(248,9,9,1);\"><b>你是否看好老年癡呆概念股？</b></span></li> \n</ul> <p>精彩留言用戶可獲得888社區積分噢！</p></body></html>","text":"今天，美國食品和藥物管理局FDA批准了$百健(BIIB)$ 的阿爾茨海默氏症（老年癡呆症）治療藥物Aduhelm，公司股價盤中一度大漲60%：據阿爾茨海默氏症協會估計，有超過600萬美國人患有此病，因爲無法得到有效的治療，到2050年，這一數字預計將上升到近1300萬。據有關專家分析，我國老年癡呆症患者比美國還要嚴重，數量可能是美國的2倍。得了老年癡呆症的人，會逐漸喪失記憶力，直到喪失動機力、無法自理，最終喪失身體機能，導致死亡。這種破壞記憶的疾病是美國第六大死亡原因，治療選擇非常有限，診斷後的平均餘命僅爲爲三到九年。 百健的藥物獲批是革命性的，因爲這是美國批准的第一種減緩老年癡呆症認知能力下降的藥物，也是近20年來第一種治療該疾病的新藥，對於老年癡呆症患者來說就是救命神藥。 除了百健外，其他阿爾茨海默病領域的公司也在爭取獲得批准: $Cassava Sciences Inc(SAVA)$ 一度大漲17%；$禮來(LLY)$一度大漲12%。 更多相關閱讀請看：老年癡呆症有救了 ！20年來第一次，FDA批准百健新藥 …… 最後，大家聊一聊： 你是否看好老年癡呆概念股？ 精彩留言用戶可獲得888社區積分噢！","highlighted":2,"essential":2,"paper":2,"link":"https://ttm.financial/post/117128195","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["BIIB","LLY","SAVA"],"verified":1,"subType":2,"readableState":1,"subTypeObject":{"tweetId":117128195,"totalAmount":888,"balance":0,"end":true,"deadline":1623484022713,"description":"528 tiger-coins have been distributed to 6 participants","remainingNumber":94},"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":false,"causeOfNotShareable":"Under review, please try again later","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":871,"xxTargetLangEnum":"ZH_HK"},"isVote":1,"tweetType":1,"viewCount":246,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}